Highlights SAB Biotherapeutics, Inc.

Stocks

SABS

US78397T2024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:10:56 2026-06-11 pm EDT			5-day change	1st Jan Change
3.320 ^USD	+0.30%		-4.61%	-11.50%

Jun. 01	SAB Biotherapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026
May. 29	SAB Biotherapeutics, Inc. Presents Data On SAB-142 At The American Diabetes Association?s 2026 Scientific Sessions And FOCIS 2026 Annual Meeting	CI

Highlights

May. 29	SAB Biotherapeutics, Inc. Presents Data On SAB-142 At The American Diabetes Association?s 2026 Scientific Sessions And FOCIS 2026 Annual Meeting	CI
May. 12	SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 22	Sab Biotherapeutics, Inc. Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes	CI
Mar. 18	SAB Biotherapeutics Launches $85 Million Stock Offering	MT
Mar. 17	Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share	RE
Mar. 17	SAB Biotherapeutics Launches Public Offering of Shares, Warrants	MT
Mar. 10	SAB Biotherapeutics Inc Announces Additional Phase 1 Data for SAB 142 in Adult Patients with Established Autoimmune Type 1 Diabetes	CI
Mar. 09	SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 18	First Patient Dosed in SAB Biotherapeutics, Inc.'S Safeguard Clinical Trial of Sab-142 for the Treatment of Stage 3 T1d	CI
Dec. 17	SAB Biotherapeutics, Inc. Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D	CI
Dec. 08	Sab Biotherapeutics, Inc. to Present Data Showcasing Progress in the Development of SAB-142 At the Asian Conference on Innovative Therapies for Diabetes Management	CI
Nov. 14	SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-19	SAB Biotherapeutics, Inc. Highlights Data in Multiple Presentations at EASD	CI
25-08-07	SAB Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-07	SAB Bio reports strong cash position with completed financing extending operational runway	RE
25-05-09	SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-28	SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142	CI
24-11-06	SAB Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-28	Oppenheimer Initiates SAB Biotherapeutics at Outperform With $12 Price Target	MT
24-08-08	SAB Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-21	FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics	CI
24-05-20	SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-16	SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	CI
24-03-29	SAB Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI